| Examination, 2022-23 | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--------|
| MPL103 | | | | | | | | | | |
| Course Name: PHARMA | | | | | | | | | | |
| Year: First Year | | | | | | | | | | |
| Branch: M Pharm | | | | | | | | | | |
| Subject: Pharmacological and Toxicological Screening Methods | | | | | | | | | | |
| Time – 3 hoursMaximum marks- 75 | | | | | | | | | | xs- 75 |

SECTION A

10X02=20

Attempt all questions

- 1. Pyloric ligation method is used to study Activity in animal.
- 2. Enlist any two *in vivo* methods used for diarrhoea evaluation in rat.
- 3. Simplest and most economic model used for cancer is
- 4. Term Aphrodisiac means
- 5. Plus- maze model is used to detect activity in animals.
- 6.are called smart drugs because
- 7. Hazelnut extract given by transdermal route causein animals.
- 8. Give the reason for selection of streptozotoc in over alloxan for induction of diabetes in rats.
- 9. Allergic contact dermatitis is
 - a) A non-immune response caused by a direct action of an agent on the skin
 - b) An immediate type I hypersensitivity reaction
 - c) A delayed type IV hypersensitivity reaction
 - d) Characterized by the intensity of reaction being proportional to the elicitation dose.
- 10. Which of the following concerning the use of the "benchmark dose" in risk assessment is NOT correct?
 - a) Can use the full range of doses and responses studied.

b) Allows use of data obtained from experiments where a clear "no observed adverse effect level" (NOAEL) has been attained.

c) May be defined as the lower confidence limit on the 10% effective dose.

d) Is primarily used for analyses of carcinogenicity data and has limited utility for analyses of developmental and reproduction studies that generate quantal data.

SECTION B

2X10=20

Attempt any two

- 11. Elaborate immune assay, interpret methods for evaluation of immune assay in relation to insulin or digoxin.
- 12. Analyse the applications of transgenic animals in modern pharmacological experimentation along with their methods of production and maintenance.
- 13. Interpret different animal models used for neurodegenerative diseases.

SECTION C

Attempt any five questions- (5X7=35)

- 14. Illustrate the limitations of experimentation in animal models, describe some alternate for animal experimentation.
- 15. Quote the principle of bioassay and analyse different methods used in animal experimentation.
- 16. Demonstrate *in vivo* animal models for anti-depressants.
- 17. Distinguish the methods of extrapolation of *in vitro* data to preclinical and preclinical data to humans.
- 18. Summarize CPCSEA guidelines for maintenance, breeding and conducting experiments on animals.
- 19. Extend any two in vitro methods for detection of anti-inflammatory activity.
- 20. Write a note on general principles of preclinical screening and enlist techniques of euthanasia used for experimental animals.
- 21. Enlist and explain any two models for anti-epileptic study.
- 22. Describe types of animals used in laboratory also mention application of different species and strains.